Djurec M, Grana O, Lee A, Troulé K, Espinet E, Cabras L, et al
. Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. Proc Natl Acad Sci U S A. 2018;115:E1147-E1156 pubmed publisher
..Moreover, high levels of SAA1 in the stromal component correlate with worse survival. These findings support the concept that selective inhibition of SAA1 in CAFs may provide potential therapeutic benefit to PDAC patients. ..
HernÃ¡ndez Porras I, Fabbiano S, Schuhmacher A, Aicher A, CaÃ±amero M, CÃ¡mara J, et al
. K-RasV14I recapitulates Noonan syndrome in mice. Proc Natl Acad Sci U S A. 2014;111:16395-400 pubmed publisher
..Perhaps more importantly, they should be useful as a preclinical model to test new therapies aimed at preventing or ameliorating those deficits associated with this syndrome. ..
Blasco M, Navas C, Martín Serrano G, Graña Castro O, Lechuga C, Martin Diaz L, et al
. Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. Cancer Cell. 2019;35:573-587.e6 pubmed publisher
..These results open the door to the development of targeted therapies for PDAC patients. ..
HernÃ¡ndez Porras I, Guerra C. Modeling RASopathies with Genetically Modified Mouse Models. Methods Mol Biol. 2017;1487:379-408 pubmed
..Here, we review a wide range of genetically modified mouse models used in the study of RASopathies and the potential application of novel technologies, which hopefully will help us resolve open questions in the field. ..
Guerra C, Collado M, Navas C, Schuhmacher A, Hernández Porras I, Canamero M, et al
. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell. 2011;19:728-39 pubmed publisher
..These results support the concept that antiinflammatory treatment of people diagnosed with pancreatitis may reduce their risk of developing PDAC. ..